Company intelligence / Profile preview
Neurodon
Crown Point, Indiana, United Statesneurodon.net ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Neurodon has several compounds in preclinical development that have shown efficacy in animal models for various diseases. Their diabetes drug NDC-0009 has demonstrated the ability to restore beta cell health in several disease models. The company was planning to initiate clinical trials in the second half of 2022 for their diabetes program.
- Therapeutic areas
- DermatologyEndocrinologyRare DiseasesNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
JDRFHarvard Medical School (Kajimura Lab)Purdue UniversityNorthwestern University
Beyond the preview
Go deeper on Neurodon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurodon.